HILLSTREAM BIOPHARMA INC (HILS) Stock Price, Forecast & Analysis
USA - NASDAQ:HILS - US4327051011 - Common Stock
HILS Key Statistics, Chart & Performance
The current stock price of HILS is 0.2305 USD. In the past month the price decreased by -4.75%. In the past year, price decreased by -70.5%.
HILS Latest News, Press Relases and Analysis
HILS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.78B | ||
| AMGN | AMGEN INC | 15.48 | 182.21B | ||
| GILD | GILEAD SCIENCES INC | 14.96 | 152.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.72 | 110.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.99 | 71.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 886.18 | 59.24B | ||
| INSM | INSMED INC | N/A | 40.94B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 9.53 | 23.39B | ||
| INCY | INCYTE CORP | 16.85 | 21.12B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.4 | 20.77B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.24 | 14.61B |
Related stock screener links
About HILS
Company Profile
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.
Company Info
HILLSTREAM BIOPHARMA INC
1200 Route 22 East, Suite 2000
Bridgewater NEW JERSEY US
Employees: 1
Phone: 19089553140.0
HILLSTREAM BIOPHARMA INC / HILS FAQ
What does HILLSTREAM BIOPHARMA INC do?
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.
What is the current price of HILS stock?
The current stock price of HILS is 0.2305 USD. The price increased by 2.76% in the last trading session.
Does HILLSTREAM BIOPHARMA INC pay dividends?
HILS does not pay a dividend.
How is the ChartMill rating for HILLSTREAM BIOPHARMA INC?
HILS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy HILS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HILS.
Can you provide the upcoming earnings date for HILLSTREAM BIOPHARMA INC?
HILLSTREAM BIOPHARMA INC (HILS) will report earnings on 2023-11-06.
Can you provide the ownership details for HILS stock?
You can find the ownership structure of HILLSTREAM BIOPHARMA INC (HILS) on the Ownership tab.
HILS Technical Analysis
HILS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HILS. While HILS seems to be doing ok healthwise, there are quite some concerns on its profitability.
HILS Financial Highlights
Over the last trailing twelve months HILS reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS decreased by -160.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
HILS Forecast & Estimates
6 analysts have analysed HILS and the average price target is 4.08 USD. This implies a price increase of 1670.07% is expected in the next year compared to the current price of 0.2305.